CN1857475A - Composition for preventing and treating cardias and cerebral vascular diseases and its application - Google Patents
Composition for preventing and treating cardias and cerebral vascular diseases and its application Download PDFInfo
- Publication number
- CN1857475A CN1857475A CNA2006102003264A CN200610200326A CN1857475A CN 1857475 A CN1857475 A CN 1857475A CN A2006102003264 A CNA2006102003264 A CN A2006102003264A CN 200610200326 A CN200610200326 A CN 200610200326A CN 1857475 A CN1857475 A CN 1857475A
- Authority
- CN
- China
- Prior art keywords
- folium
- compositions
- crataegi
- extract
- monas cuspurpureus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to one composition for preventing and treating cardiac and cerebral vascular diseases and the composition may be used as medicine, health food or health food additive. The composition consists of red yeast and haw or haw leaf, and may contain gingko leaf and lotus leaf. The composition is used in preventing and treating hypertension, hyperlipemia, etc causing cardiac and cerebral vascular diseases, and has determined curative effect and no toxic side effect.
Description
Technical field
The invention belongs to medicine and field of food, particularly relate to the compositions of a kind of prevention and treatment cardiovascular and cerebrovascular disease.Said composition can be used as medicinal, also can make health food or food additive and use.
Background technology
Cardiovascular and cerebrovascular disease and diabetes, tumor are at present the mankind to be threatened maximum three major types disease.Wherein cardiovascular and cerebrovascular disease is positioned at first of this three major types disease, and reason is that it not only has very high fatality rate, and causes patient's disability rate also high after its morbidity.Since 1958, the sickness rate of China's cardiovascular and cerebrovascular disease has risen 4 times, and especially the incidence rate of apoplexy is far above American-European countries.China is annual because the medical expense that cardiovascular and cerebrovascular disease spent and labour force's loss exceed 2,000 hundred million yuan, causes white elephant for society and family, expects the year two thousand twenty, and the total dead burden of coronary heart disease and cerebro-vascular diseases also will double.So prevention and treatment cardiovascular and cerebrovascular disease have become the important and arduous problem of pendulum in face of us.In developed country, prevention, treatment, the Trinitarian way of rehabilitation are obtaining remarkable result aspect the M ﹠ M of control cardiovascular and cerebrovascular disease.And China is based on treatment at present, and rehabilitation is auxilliary, prevents this link relatively poor.In the cardiovascular and cerebrovascular disease chain, the multiple risk factor (as hyperlipidemia, hypertension) that inspires cardiovascular and cerebrovascular disease belongs to the upstream of closing tethers, and diabetes and metabolic syndrome belong to middle reaches, and angina cordis, myocardial infarction and apoplexy etc. belong to the downstream of disease chain.Disturbing the downstream is a kind of expensive high risk pattern to the treatment in disease latter stage, transfers to the upstream then risk is little as intervening emphasis, with low cost, sufficient choice is arranged, can alleviate patient's misery, reduce influence, save medical resource greatly work and quality of life.
Hyperlipidemia and hypertension all are the risk factors that causes cardiovascular and cerebrovascular disease, are the primary prevention indexs of two important cardiovascular and cerebrovascular diseases.Hyperlipidemia further develops, and will cause arteriosclerosis.Studies show that dyslipidemia mainly influences bigger blood vessel, and hypertension influences the little blood vessel of intracranial.The pathological change of cerebral hemorrhage mainly is a hypertensive arteriosclerosis, shows as small artery degeneration, necrosis, formation microaneurysm, so that it is hemorrhage to break.Hypertension is the principal element that causes apoplexy, coronary heart disease.The medicament categories of treatment cardiovascular and cerebrovascular disease is various at present, and treatment hyperlipidemia medicine mainly contains on the market: Statins, the special class of shellfish, bile acid intercalating agent and nicotinic acid class; Treat hypertensive medicine commonly used be: diuretic,?-receptor blocking agent, calcium antagonist, angiotensin converting enzyme inhibitor and Q receptor blocking agent or the like.With these medicines the control of cardiovascular and cerebrovascular disease has been obtained certain effect clinically, but mechanism of action is more single, it is obvious to take side effect for a long time, and patient's body and mind is caused harmful effect.Chinese medicine has prevention and advantage such as toxic and side effects is little, day by day at home and abroad obtains paying attention to and application.It is low to seek a kind of cost, determined curative effect, and the natural Chinese medicines preparation that has no side effect is very urgent.Contrast after deliberation, we develop the compositions of a kind of prevention and treatment cardiovascular and cerebrovascular disease, said composition is made up of Monas cuspurpureus Went, Fructus Crataegi, can further help on this basis with Folium Ginkgo, Folium Nelumbinis.Monas cuspurpureus Went, Fructus Crataegi, Folium Ginkgo, Folium Nelumbinis all are not only pharmaceutically acceptable but also edibles, and safe without toxic side effect is used for the control of cardiovascular and cerebrovascular disease, and the blood fat-reducing blood pressure-decreasing determined curative effect conforms to the thought of motherland's medical science " medication of dietetic therapy victory ".Up to now, the report that does not have above-mentioned compatibility agent.
Summary of the invention
The object of the present invention is to provide the compositions of a kind of prevention and treatment cardiovascular and cerebrovascular disease, utilize Monas cuspurpureus Went, Fructus Crataegi blood circulation promoting and blood stasis dispelling, both are combined into novel formulation develop research, by compatibility bring into play both in blood fat reducing, prevent and treat the cooperative compensating effect of aspects such as hypertension, coronary heart disease, be that this type of treatment of diseases increases a new medication and selects.On the basis of above-mentioned Monas cuspurpureus Went, Fructus Crataegi compositions, as add and join Folium Ginkgo or Folium Nelumbinis and use, or add simultaneously and join Folium Ginkgo and Folium Nelumbinis use, it is further strengthened in blood fat reducing, the cooperative compensating effect of preventing and treating aspects such as hypertension, coronary heart disease.Above-mentioned composition can be used as medicinal, also can make health product or food additive and use.
Monas cuspurpureus Went is the pure natural fermented product, and the edible history of existing more than one thousand years is natural food dye, and edible adding uses agent, the traditional Chinese medical science to think precious health care tonic.Fructus Crataegi, Folium Nelumbinis are the Chinese medicine of the integration of edible and medicinal herbs of state approval, Folium Ginkgo is the Chinese medicine that state approval can be used for health food, its effective ingredient, pharmacology, drug effect, clinical practice etc. have a large amount of bibliographical informations, and the present invention does not repeat them here, and only do one below and simply introduce.
Monas cuspurpureus Went (also name Monas cuspurpureus Went) is to be raw material with the rice, and a kind of aubergine rice-koji that forms through the monascus fermentation is so claim red song again.The invention of Monas cuspurpureus Went is the history in existing more than 1,000 year so far.Be widely used in aspects such as wine brewing, food color, food fermentation and Chinese medicine.The essentials of Matea Medica that Ancient Times in China is shown, Compendium of Material Medica etc. all have the record of Monas cuspurpureus Went drug effect." the Chinese medicine dictionary " that China publishes rescued the main medicine of Monas cuspurpureus Went and reduced " blood circulation promoting and blood stasis dispelling, strengthening the spleen to promote digestion, treatment prolonged lochia, the stagnant stomachache of the stasis of blood, glutted, the red white dysentery of food stagnation and traumatic injury ".In recent years coming year, Chinese scholars is goed deep into day by day to the pharmacological active substance research of Monas cuspurpureus Went, find that Monas cuspurpureus Went has effects such as blood fat reducing, blood pressure lowering, blood sugar lowering, anti-cancer, the effective ingredient lovastatin that extracts from Monas cuspurpureus Went has become the choice drug of treatment adult hyperlipidemia in the west, large usage quantity is one of medicine salable in the world.In China, the single preparations of ephedrine of Monas cuspurpureus Went also goes on the market, as XUEZHIKANG JIAONANG, zhibituo sheet.
Fructus Crataegi is traditional Chinese medicine, and really, nuclear, Ye Junke is used as medicine, medicinal record head sees Collective Notes to the Canon of Materia medica.The traditional Chinese medical science is thought, Fructus Crataegi energy appetite-stimulating indigestion-relieving, and removing food stagnancyization stagnates, activating blood circulation to dissipate blood stasis, convergence dysentery relieving.Modern pharmacological research finds that its complex chemical composition contains compositions such as flavone, terpenoid, glycoside, organic acid, vitamin C, riboflavin, carotene.Have facilitating digestion, blood pressure lowering, blood fat reducing, increase coronary flow, arrhythmia, protection human vascular endothelial, bacteriostasis, antitumor action, in addition protect in addition retina, suppress multiple effects such as distortion.Not only can be used for treating cardiovascular system diseases, digestive system disease and gynaecopathia, also be widely used in prevention, health care, body-building and beauty treatment, is the common Chinese medicine of medicine-food two-purpose.
Ginkgo is China special product plant, and the resource owning amount accounts for more than 70% of world's total amount.The traditional Chinese medical science think Folium Ginkgo can activating blood circulation to dissipate blood stasis, TONGMAI SHULUO.Contain flavone compound, terpene lactone, polyisoamylene alcohols in the Folium Ginkgo, also have organic acid, alkyl phenol and alkyl phenolic acid, steroidal compounds and trace element etc. in addition.Have and improve the heart and brain blood circulation, prevent arteriosclerosis, remove blood fat rubbish, suppress platelet aggregation, prevent the good action of cerebral thrombosis, and have the person in middle and old age's of preventing dementia, retina apart from change, enhancing immunity, antioxidation, powers such as slow down aging.
Folium Nelumbinis is the dried leaves of nymphaeaceae plant lotus.Compendium of Material Medica is carried " Folium Nelumbinis is obeyed it, makes us thin bad ".Traditional medicine thinks that liver, spleen, stomach are put down, returned to the Folium Nelumbinis hardship, has the effect of removing summer-heat, sending up the lucid YANG, cooling blood for hemostasis.Folium Nelumbinis also contains multiple alkaloid and flavone compound except that containing routine chemical componentses such as the common carbohydrate of common plant, lipid, protein, tannin.Have effects such as fat-reducing slimming, blood pressure lowering, antibacterial, antioxidation.
Purpose of the present invention realizes by following measure:
The compositions of a kind of prevention or treatment cardiovascular and cerebrovascular disease, said composition is that active ingredient is formulated with Monas cuspurpureus Went and Fructus Crataegi.Monas cuspurpureus Went: the weight ratio of Fructus Crataegi is 1-30: 1-30.
On the basis of Monas cuspurpureus Went, Fructus Crataegi compositions, can add and join Folium Ginkgo.
Monas cuspurpureus Went: Folium Crataegi: the weight ratio of Folium Ginkgo is 1-30: 1-30: 0-30.
On the basis of Monas cuspurpureus Went, Fructus Crataegi compositions, can add and join Folium Nelumbinis.
Monas cuspurpureus Went: Folium Crataegi: the weight ratio of Folium Nelumbinis is 1-30: 1-30: 0-30.
On the basis of Monas cuspurpureus Went, Fructus Crataegi compositions, can add simultaneously and join Folium Ginkgo, Folium Nelumbinis.
Monas cuspurpureus Went: Folium Crataegi: Folium Ginkgo: the weight ratio of Folium Nelumbinis is 1-30: 1-30: 0-30: 0-30.
Fructus Crataegi in the above-mentioned composition can substitute with Folium Crataegi.
Above-mentioned Monas cuspurpureus Went can for Hongqu powder (red colouring agent), Monas cuspurpureus Went extract the two one of, or any mixing of the two.
Above-mentioned Fructus Crataegi can for Fructus Crataegi powder, Fructus Crataegi extract the two one of, or any mixing of the two.
Above-mentioned Folium Crataegi can for Folium Crataegi powder, Folium Crataegi extract the two one of, or any mixing of the two.
Above-mentioned Folium Ginkgo can for ginkgo leaf powder, Folium Ginkgo extract the two one of, or any mixing of the two.
Above-mentioned Folium Nelumbinis can for Folium Nelumbinis powder, Folium Nelumbinis extract the two one of, or any mixing of the two.
The said extracted thing comprises effective site, the effective ingredient of extract.Above-mentioned Monas cuspurpureus Went and extract thereof, effective site and effective ingredient all can be used as raw material; Above-mentioned Folium Crataegi and extract thereof, effective site and effective ingredient all can be used as raw material; Above-mentioned Folium Ginkgo and extract thereof, effective site and effective ingredient all can be used as raw material; Above-mentioned Folium Nelumbinis and extract thereof, effective site and effective ingredient all can be used as raw material.
Above-mentioned composition and medically acceptable carrier or excipient are made various preparations, can be tablet, capsule, granule, powder, pill, medicated wine, oral liquid, medicinal tea etc.
Described tablet comprises all kinds of tablets such as ordinary tablet, effervescent tablet, dispersible tablet, oral cavity disintegration tablet; Described capsule comprises all kinds of capsules such as soft capsule, hard capsule; Described granule includes all kinds of granules such as sugared type, Sugarless type, effervescence type; Described pill comprises all kinds of pills such as the watered pill, honeyed pill, water-honeyed pill, concentrated pill, drop pill, micropill.
Compositions of the present invention is removed as medicine, the application aspect health food or food additive.Said composition can be applicable to health food or food additive, as, blood fat reducing based food, as the pigment interpolation etc., human body is had certain health care, and prevention or treatment cardiovascular and cerebrovascular disease are had certain function of health care.
The combination of Monas cuspurpureus Went, Fructus Crataegi/Folium Crataegi, Folium Ginkgo and Folium Nelumbinis prescription has been carried out the medicine efficacy screening of system, found that to share to have synergism, the drug effect enhancing with Monas cuspurpureus Went and Fructus Crataegi/Folium Crataegi.Add and join that total effective rate increases behind Folium Ginkgo, the Folium Nelumbinis.
Experimental example 1: spontaneous hypertensive rat blood pressure lowering experiment
80 routine spontaneous hypertensive rats are divided into 8 groups at random according to basic blood pressure value level, and 10 every group, male and female half and half.Be subjected to reagent thing group per os to irritate stomach and give to be subjected to accordingly the reagent thing, matched group is irritated stomach and is given distilled water, be subjected in the reagent thing group first group to be Monas cuspurpureus Went, second group is Monas cuspurpureus Went: Fructus Crataegi (1: 1), the 3rd group is Monas cuspurpureus Went: Folium Crataegi (1: 1), the 4th group is Monas cuspurpureus Went: Fructus Crataegi: Folium Ginkgo (1: 0.5: 0.5), the 5th group is Monas cuspurpureus Went: Fructus Crataegi: Folium Nelumbinis (1: 0.5: 0.5), the 6th group is Monas cuspurpureus Went: Fructus Crataegi: Folium Ginkgo: (1: 0.5: 0.3: 0.2), the 7th group was Monas cuspurpureus Went to Folium Nelumbinis: Folium Crataegi: Folium Ginkgo: Folium Nelumbinis (1: 0.5: 0.3: 0.2).Continuously 4 weeks of feed, pressure measurement is 1 time weekly.The results are shown in Table 1.By table 1 as seen, be subjected to the reagent thing after 2 weeks, be subjected to the reagent thing second group to the 7th group the resisting hypertension effect to be arranged promptly, each group all has tangible resisting hypertension effect after 3 weeks, and 4 all backs effects are more remarkable.
Table 1 spontaneous hypertensive rat blood pressure lowering experimental result (x ± s, mmHg)
| Group | 0 week | 1 week | 2 weeks | 3 weeks | 4 weeks |
| Matched group | 245.58± 24.21 | 276.28±21.40 | 273.03± 18.51 | 276.85±29.57 | 282.74± 16.11 |
| First group | 245.14± 32.05 | 262.37±25.14 | 260.31± 27.44 | 257.53±9.57 | 255.49± 27.08 |
| Second group | 245.26± 27.16 | 257.76±24.33 | 255.92± 16.89 | 244.92±20.04 | 245.32± 11.08 |
| The 3rd group | 245.79± 19.01 | 255.31±18.42 | 254.11± 20.01 | 244.29±23.05 | 241.27± 17.25 |
| The 4th group | 245.22± 26.73 | 251.33±24.27 | 248.62± 21.06 | 240.34±0.08 | 239.04± 27.20 |
| The 5th group | 245.09± 26.38 | 252.42±18.36 | 250.97± 26.21 | 242.74±21.53 | 240.61± 22.15 |
| The 6th group | 245.10± 20.07 | 250.76±20.05 | 246.16± 22.18 | 240.05±21.30 | 238.09± 23.41 |
| The 7th group | 245.52± 22.64 | 251.07±18.54 | 245.62± 23.32 | 241.53±27.12 | 240.44± 19.34 |
Experimental example 2: hyperlipidemia rats lipid-lowering test
The rat feeding normal feedstuff observed for 2 weeks under experimental situation, got tail blood, surveyed the normal value of TC observation index, and recording the Serum TC value is 1.77mmol/L.Begin from formal experiment, each treated animal fed for 3 weeks with high lipid food, got tail blood, and recording the Serum TC value is 3.25mmol/L, with normal value the difference of highly significant, experimental hyperlipemia in rats modelling was arranged.According to the TC level, carry out random packet, be divided into 8 groups, 8 every group, male and female half and half.Be subjected to reagent thing group per os to irritate stomach and give to be subjected to accordingly the reagent thing, matched group is irritated stomach and is given distilled water, is subjected to reagent thing group to be divided into seven groups again, with experimental example 1, continues to give high lipid food, 4 weeks of feed, get tail blood, and measure the every index of blood fat.The results are shown in Table 2.By table 2 as seen, be subjected to reagent thing group that tangible hyperlipidemia effect is all arranged, the 3rd group to the 7th group effect is more remarkable.
Table 2 hyperlipidemia rats lipid-lowering test result (x ± s, mmol/L)
| Group | TC | TG | LDL-C | |||
| Before the test | Test is not | Before the test | Test is not | Before the test | Test is not | |
| Matched group | 3.17±0.28 | 3.17±0.34 | 1.83±0.35 | 1.80±0.26 | 2.23±0.51 | 2.25±0.40 |
| First group | 3.18±0.30 | 2.41±0.31 | 1.78±0.42 | 1.38±0.31 | 2.34±0.46 | 1.46±0.49 |
| Second group | 3.20±0.31 | 2.12±0.37 | 1.86±0.38 | 1.21±0.24 | 2.29±0.38 | 1.10±0.27 |
| The 3rd group | 3.19±0.30 | 2.11±0.36 | 1.65±0.51 | 1.23±0.15 | 2.41±0.43 | 1.12±0.36 |
| The 4th group | 3.19±0.32 | 2.08±0.40 | 1.84±0.44 | 1.19±0.28 | 2.15±0.36 | 0.89±0.40 |
| The 5th group | 3.20±0.29 | 2.10±0.35 | 1.59±0.38 | 1.20±0.33 | 2.20±0.40 | 1.02±0.35 |
| The 6th group | 3.17±0.31 | 2.05±0.41 | 1.70±0.37 | 1.17±0.35 | 2.44±0.29 | 0.80±0.41 |
| The 7th group | 3.18±0.27 | 2.04±0.36 | 1.81±0.45 | 1.18±0.40 | 2.28±0.34 | 0.77±0.36 |
Experimental example 3: drug regimen compatibility blood fat reducing curative effect relatively
Hyperlipemia 75 examples, got rid of the hyperlipidemia that causes because of diabetes, acute and chronic liver and gall diseases, the nephrotic syndrome, gout, be divided into 5 groups at random, every group 15 example, indexs such as patient age, sex, severity extent are learned by statistics and are handled no significant difference (P＜0.05).Take medicine by group respectively, every day, secondary was for 8 weeks the course of treatment, avoided using other to influence the medicine of blood fat during being tried.Criterion of therapeutical effect is divided into produce effects, effective, invalid.Produce effects: empty stomach serum TC5.17-6.18mmol/L, TG1.47-1.80mmol/L, LDL-C3.36-4.11mmol/L, HDL-C 〉=1.16mmol/L, complication is obviously improved; Effectively: TC6.19-6.21mmol/L, TG1.81-1.85mmol/L, LDL-C4.12-4.14mmol/L, HDL-C0.93-1.16mmol/L, complication has improvement; Invalid: serum lipids and complication are improved not obvious.Therapeutic outcome sees Table 3.
Table 3 blood fat reducing curative effect relatively
| Numbering | Monas cuspurpureus Went | Fructus Crataegi | Semen Ginkgo | Folium Nelumbinis | Produce effects | Effectively | Invalid | Total effective rate (%) |
| 1 | 2 | 0 | 0 | 0 | 6 | 4 | 5 | 67 |
| 2 | 1 | 1 | 0 | 0 | 9 | 5 | 1 | 93 |
| 3 | 1 | 0.5 | 0.5 | 0 | 11 | 3 | 1 | 93 |
| 4 | 1 | 0.5 | 0 | 0.5 | 11 | 4 | 0 | 100 |
| 5 | 1 | 0.5 | 0.3 | 0.2 | 12 | 3 | 0 | 100 |
The amount of listed compositions is dose on the one in the table, and unit is g.
Experimental example 4: drug regimen compatibility blood pressure lowering curative effect relatively
Hyperpietic's 100 examples are divided into 5 groups at random, and every group 20 example, indexs such as patient age, sex, severity extent are learned by statistics and handled no significant difference (P＜0.05).Take medicine by group respectively, every day, secondary was for 8 weeks the course of treatment, avoided using other to influence the medicine of blood pressure during being tried.Criterion of therapeutical effect is divided into produce effects, effective, invalid.Produce effects: diastolic pressure (DBP) decline 〉=10mmHg, and reduce to normal range (＜90mmHg), or systolic pressure (SBP) decline 〉=20mmHg; Effectively: do not arrive 10mmHg though DBP descends, reduce to normally, or DBP decline 10-19mmHg; Invalid: as not reach above-mentioned horizontal person.Therapeutic outcome sees Table 4.
Table 4 blood pressure lowering curative effect relatively
| Numbering | Monas cuspurpureus Went | Fructus Crataegi | Semen Ginkgo | Folium Nelumbinis | Produce effects | Effectively | Invalid | Total effective rate (%) |
| 1 | 2 | 0 | 0 | 0 | 5 | 7 | 8 | 60 |
| 2 | 1 | 1 | 0 | 0 | 8 | 8 | 4 | 80 |
| 3 | 1 | 0.5 | 0.5 | 0 | 10 | 8 | 2 | 90 |
| 4 | 1 | 0.5 | 0 | 0.5 | 9 | 8 | 3 | 85 |
| 5 | 1 | 0.5 | 0.3 | 0.2 | 11 | 7 | 2 | 90 |
The amount of listed compositions is dose on the one in the table, and unit is g.
The beneficial effect of compositions of prevention of the present invention and treatment cardiovascular and cerebrovascular disease is mainly reflected in: said composition is made up of Monas cuspurpureus Went, Fructus Crataegi/Folium Crataegi, can help again on this basis with Folium Ginkgo, Folium Nelumbinis.The above-mentioned composition compatibility, effect strengthens, the high risk factor hyperlipidemia that causes cardiovascular and cerebrovascular disease, hypertension etc. are prevented and treated, determined curative effect, intervene the upstream risk factor in the cardiovascular and cerebrovascular disease chain, can effectively reduce medical-risk, alleviate patient's misery, reduce influence, save medical resource greatly work and quality of life.Used raw material is the natural product of medicine-food two-purpose in the said composition, and is fool proof, has no side effect, and can be used as health food and takes for a long time, and the one-level that is applied to cardiovascular and cerebrovascular disease is anti-pre-.The cardiovascular and cerebrovascular disease course of disease is long, the medical expense height, and the external at present statinses that adopt are prevented and treated more, the expense height, and in safety, remain generally dispute.Compositions involved in the present invention is raw materials used very abundant in China, cheap and easy to get, can reduce greatly and control the required economy expenditure of cardiovascular and cerebrovascular disease in advance, and can drive the development of related industry, and have very strong realistic meaning, be the splendid method of control cardiovascular and cerebrovascular disease.
The specific embodiment
Following embodiment is used to further specify the present invention, but does not limit the scope of the invention thus.
Embodiment 1
Monas cuspurpureus Went becomes fine powder with Fructus Crataegi/Folium Crataegi pulverize separately, and in 1: 1 ratio, mixing promptly got compositions of the present invention.
Embodiment 2
Monas cuspurpureus Went becomes fine powder with Fructus Crataegi/Folium Crataegi pulverize separately, and in 1: 0.5 ratio, mixing promptly got compositions of the present invention.
Embodiment 3
Monas cuspurpureus Went becomes fine powder with Fructus Crataegi/Folium Crataegi pulverize separately, and in 1: 30 ratio, mixing promptly got compositions of the present invention.
Embodiment 4
Monas cuspurpureus Went becomes fine powder with Fructus Crataegi/Folium Crataegi pulverize separately, and in 30: 1 ratio, mixing promptly got compositions of the present invention.
Embodiment 5
Hongqu powder (red colouring agent), Monas cuspurpureus Went extract, Fructus Crataegi extract were in 1: 0.5: 0.3 ratio, and mixing promptly gets compositions of the present invention.
Embodiment 6
Monas cuspurpureus Went, Folium Crataegi, Folium Ginkgo pulverize separately become fine powder, and in 1: 0.5: 0.5 ratio, mixing promptly got compositions of the present invention.
Embodiment 7
Monas cuspurpureus Went, Folium Crataegi, Folium Ginkgo pulverize separately become fine powder, and in 3: 1: 1 ratio, mixing promptly got compositions of the present invention.
Embodiment 8
Monas cuspurpureus Went, Folium Crataegi, Folium Ginkgo pulverize separately become fine powder, and in 30: 5: 1 ratio, mixing promptly got compositions of the present invention.
Embodiment 9
Monas cuspurpureus Went, Folium Crataegi, Folium Nelumbinis pulverize separately become fine powder, and in 1: 0.5: 0.5 ratio, mixing promptly got compositions of the present invention.
Embodiment 10
Monas cuspurpureus Went, Folium Crataegi, Folium Ginkgo, Folium Nelumbinis pulverize separately become fine powder, and in 1: 0.5: 0.3: 0.2 ratio, mixing promptly got compositions of the present invention.
Embodiment 11
Hongqu powder (red colouring agent) extracts secondary with 70% alcohol heating reflux, and each 1 hour, filter, reclaim ethanol, concentrate drying for standby; The Folium Crataegi powder extracts secondary with 70% alcohol heating reflux, and each 1 hour, filter, reclaim ethanol, concentrate drying for standby; With the dry extract of the gained ratio in 1: 1, mixing promptly gets compositions of the present invention.
Embodiment 12
Monas cuspurpureus Went, Folium Crataegi, Folium Ginkgo, Folium Nelumbinis extract secondary with 50% alcohol heating reflux respectively, and each 1 hour, filter, reclaim ethanol, concentrate drying for standby; With the dry extract of gained in 1: 0.5: 0.3: 0.2 ratio, mixing promptly gets compositions of the present invention.
Embodiment 13
Hongqu powder (red colouring agent), Folium Crataegi extract (conventional method makes), Folium Ginkgo extract (conventional method makes) were in 1: 0.3: 0.2 ratio, and mixing promptly gets compositions of the present invention.
Embodiment 14
Hongqu powder (red colouring agent), Folium Crataegi extract (conventional method makes), Folium Ginkgo extract (conventional method makes), Folium Nelumbinis extract (conventional method makes) were in 1: 0.3: 0.3: 0.2 ratio, mixing promptly gets compositions of the present invention.
Embodiment 15
Hongqu powder (red colouring agent), Folium Crataegi powder, Folium Crataegi extract (conventional method makes), Folium Ginkgo extract (conventional method makes), Folium Nelumbinis extract (conventional method makes) were in 1: 0.2: 0.3: 0.3: 0.2 ratio, mixing promptly gets compositions of the present invention.
The compositions of gained can adopt conventional method to make various preparations in the foregoing description, as incapsulates and make capsule, adds appropriate excipients, and tabletting is made tablet etc.
Claims (10)
1. the compositions of preventing and treating cardiovascular and cerebrovascular disease is characterized in that said composition is that active ingredient is formulated with Monas cuspurpureus Went and Fructus Crataegi.
2. the described compositions of claim 1 is characterized in that, the Fructus Crataegi in the compositions can substitute with Folium Crataegi.
3. the described compositions of claim 1 is characterized in that, can add in compositions and join Folium Ginkgo.
4. the described compositions of claim 1 is characterized in that, can add in compositions and join Folium Nelumbinis.
5. the described compositions of claim 1 is characterized in that, can add to join Folium Ginkgo and Folium Nelumbinis in compositions.
6. claim 1,3,4,5 described compositionss is characterized in that, described Monas cuspurpureus Went is one of the two of Hongqu powder (red colouring agent), Monas cuspurpureus Went extract, or any mixing of the two; Described Fructus Crataegi is one of the two of Fructus Crataegi powder, Fructus Crataegi extract, or any mixing of the two; Described Folium Crataegi is one of the two of Folium Crataegi powder, Folium Crataegi extract, or any mixing of the two; Described Folium Ginkgo can for ginkgo leaf powder, Folium Ginkgo extract the two one of, or any mixing of the two; Described Folium Nelumbinis can for Folium Nelumbinis powder, Folium Nelumbinis extract the two one of, or any mixing of the two.
7. the described extract of claim 5 is characterized in that, comprises effective site, the effective ingredient of extraction.
8. claim 1,3,4,5 described compositionss is characterized in that, described compositions and medically acceptable carrier or excipient are made various preparations.
9. the described preparation of claim 8 is characterized in that, can be tablet, capsule, granule, pill, teabag, medicated wine, oral liquid or other suitable any dosage form.
10. claim 1,3,4, the application of 5 described compositionss aspect health food or food additive.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2006102003264A CN1857475A (en) | 2006-04-07 | 2006-04-07 | Composition for preventing and treating cardias and cerebral vascular diseases and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2006102003264A CN1857475A (en) | 2006-04-07 | 2006-04-07 | Composition for preventing and treating cardias and cerebral vascular diseases and its application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1857475A true CN1857475A (en) | 2006-11-08 |
Family
ID=37296463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2006102003264A Pending CN1857475A (en) | 2006-04-07 | 2006-04-07 | Composition for preventing and treating cardias and cerebral vascular diseases and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1857475A (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102309571A (en) * | 2010-07-09 | 2012-01-11 | 王巧玲 | Composition for preventing and treating heart cerebrovascular disease |
| CN102048217B (en) * | 2009-10-30 | 2012-10-03 | 常堡同 | Beverage capable of reducing blood pressure and blood fat and production method thereof |
| CN101756073B (en) * | 2010-01-08 | 2013-01-23 | 杭州钱林生物科技有限公司 | Low-cholesterol chicken feedstuff additive and preparation method thereof |
| CN103372073A (en) * | 2012-04-20 | 2013-10-30 | 北京北大维信生物科技有限公司 | Red rice and hawthorn medicinal composition for regulating blood fat and preparation method of composition |
| CN103652159A (en) * | 2013-10-31 | 2014-03-26 | 安徽博格生物科技有限公司 | Tea bag for preventing and treating hyperlipidemia diseases |
| CN104274607A (en) * | 2013-07-01 | 2015-01-14 | 上海丹康实业有限公司 | Traditional Chinese medicine lipid-lowering compound preparation and preparation method thereof |
| CN104643070A (en) * | 2015-01-31 | 2015-05-27 | 扬州日兴生物科技股份有限公司 | Formula of chitosan oligosaccharide and natto flour containing diet for patients suffering from cardiovascular and cerebrovascular diseases |
| CN107773679A (en) * | 2016-08-25 | 2018-03-09 | 沈阳药科大学 | A kind of composition and its preparation technology for aiding in reducing blood lipid, aiding in thrombus |
| CN110170027A (en) * | 2019-04-23 | 2019-08-27 | 广东健信制药股份有限公司 | A kind of haw monascus powder pill and preparation method thereof |
| CN110624091A (en) * | 2019-10-25 | 2019-12-31 | 李玉保 | Ginkgo leaf compound polyphenol capsule with lipid-lowering and thrombolytic effects and preparation method thereof |
-
2006
- 2006-04-07 CN CNA2006102003264A patent/CN1857475A/en active Pending
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102048217B (en) * | 2009-10-30 | 2012-10-03 | 常堡同 | Beverage capable of reducing blood pressure and blood fat and production method thereof |
| CN101756073B (en) * | 2010-01-08 | 2013-01-23 | 杭州钱林生物科技有限公司 | Low-cholesterol chicken feedstuff additive and preparation method thereof |
| CN102309571A (en) * | 2010-07-09 | 2012-01-11 | 王巧玲 | Composition for preventing and treating heart cerebrovascular disease |
| CN103372073A (en) * | 2012-04-20 | 2013-10-30 | 北京北大维信生物科技有限公司 | Red rice and hawthorn medicinal composition for regulating blood fat and preparation method of composition |
| CN104274607A (en) * | 2013-07-01 | 2015-01-14 | 上海丹康实业有限公司 | Traditional Chinese medicine lipid-lowering compound preparation and preparation method thereof |
| CN103652159A (en) * | 2013-10-31 | 2014-03-26 | 安徽博格生物科技有限公司 | Tea bag for preventing and treating hyperlipidemia diseases |
| CN104643070A (en) * | 2015-01-31 | 2015-05-27 | 扬州日兴生物科技股份有限公司 | Formula of chitosan oligosaccharide and natto flour containing diet for patients suffering from cardiovascular and cerebrovascular diseases |
| CN107773679A (en) * | 2016-08-25 | 2018-03-09 | 沈阳药科大学 | A kind of composition and its preparation technology for aiding in reducing blood lipid, aiding in thrombus |
| CN110170027A (en) * | 2019-04-23 | 2019-08-27 | 广东健信制药股份有限公司 | A kind of haw monascus powder pill and preparation method thereof |
| CN110170027B (en) * | 2019-04-23 | 2021-06-29 | 广东健信制药股份有限公司 | Hawthorn and monascus powder pills and preparation method thereof |
| CN110624091A (en) * | 2019-10-25 | 2019-12-31 | 李玉保 | Ginkgo leaf compound polyphenol capsule with lipid-lowering and thrombolytic effects and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1857475A (en) | Composition for preventing and treating cardias and cerebral vascular diseases and its application | |
| CN103861060B (en) | Sobering-up tablet and preparation method thereof | |
| CN100563697C (en) | Rhodiola rosea hippophae rhamnoides patch and preparation method thereof | |
| CN105395919B (en) | It is a kind of to contain black fungus extract, the composition with effect for reducing blood fat and preparation method thereof | |
| US10111451B2 (en) | Food, beverage or pharmaceutical composition containing fermented eastern prickly pear and a preparation method therefor | |
| CN1840166A (en) | Modern Chinese medicinal oral liquid of 'Wen Dan Tang' and preparation method thereof | |
| CN102038745B (en) | Hypolipidemic traditional Chinese medicine | |
| CN1348717A (en) | Diatotherapeutic flour for treating diabetes and its production process | |
| CN103479691B (en) | Fat-reducing liver-protecting Chinese medicine composition | |
| CN101507800A (en) | Ludisia discolor and pumpkin composite health care product capable of reducing blood sugar and preparation method thereof | |
| CN1907386B (en) | Chinese traditional medicinal composition for treating hyperlipemia, hypertension, and coronary disease | |
| CN1939506B (en) | Preparation with blood-pressure, blood-sugar and blood-fat lowering functions and its making method | |
| CN101244084B (en) | Sobering-up agent of pearl oyster and preparation thereof | |
| CN106668451B (en) | A kind of Chinese medicine composition and its application | |
| CN104997018A (en) | Yew enzyme health-care product as well as preparation method and application thereof | |
| CN108355055A (en) | A kind of pharmaceutical composition for treating hypertension | |
| CN1948451A (en) | Health care wine and its preparation method | |
| JP2004352626A (en) | Anticholesterol agent containing plant-derived component | |
| CN102846720B (en) | Composite for lowering blood fat and improving anoxia endurance | |
| CN1115159C (en) | Red sage containing medicine composition and its preparation and use | |
| CN101669995A (en) | Composite for treatment and health care of heart cerebrovascular diseases and preparation method thereof | |
| CN105106721A (en) | Health product with efficacy of reducing blood sugar | |
| CN101347556A (en) | Composition beneficial to cardio-cerebrovascular | |
| CN1193769C (en) | Health-care food with sobering function | |
| CN1660398B (en) | Combination of medication for treating sleep disorder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20061108 |